Jonathan Miller, general counsel at the U.S. Hemp Roundtable represented hemp stakeholders at a congressional hearing last week to determine if the U.S. Food and Drug Administration (FDA) had failed to meet its charter obligations by not moving to regulate CBD.
The FDA has Membership required to view content. that it does not have the authority to regulate CBD, nor is there an existing regulatory framework for cannabinoids, they argue. FDA is reluctant to wade into cannabis. It is a complicated subject, with overlapping agency interests, and many decades of entrenched policy that makes the issue radioactive for…
Membership is required to view the rest of this post.
Click here to learn more and sign up for a free 7-day trial!
